JP2023171909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023171909A5 JP2023171909A5 JP2023172194A JP2023172194A JP2023171909A5 JP 2023171909 A5 JP2023171909 A5 JP 2023171909A5 JP 2023172194 A JP2023172194 A JP 2023172194A JP 2023172194 A JP2023172194 A JP 2023172194A JP 2023171909 A5 JP2023171909 A5 JP 2023171909A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- nucleotide sequence
- sequence
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 18
- 125000003729 nucleotide group Chemical group 0.000 claims 18
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721921P | 2018-08-23 | 2018-08-23 | |
| US62/721,921 | 2018-08-23 | ||
| JP2021510030A JP7402223B2 (ja) | 2018-08-23 | 2019-08-22 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
| PCT/US2019/047601 WO2020041537A1 (en) | 2018-08-23 | 2019-08-22 | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510030A Division JP7402223B2 (ja) | 2018-08-23 | 2019-08-22 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023171909A JP2023171909A (ja) | 2023-12-05 |
| JP2023171909A5 true JP2023171909A5 (enExample) | 2024-03-06 |
| JP7541167B2 JP7541167B2 (ja) | 2024-08-27 |
Family
ID=67876086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510030A Active JP7402223B2 (ja) | 2018-08-23 | 2019-08-22 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
| JP2023172194A Active JP7541167B2 (ja) | 2018-08-23 | 2023-10-03 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510030A Active JP7402223B2 (ja) | 2018-08-23 | 2019-08-22 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11578127B2 (enExample) |
| EP (1) | EP3840841A1 (enExample) |
| JP (2) | JP7402223B2 (enExample) |
| KR (1) | KR20210049863A (enExample) |
| CN (1) | CN112888482B (enExample) |
| AU (1) | AU2019325565B2 (enExample) |
| BR (1) | BR112021003023A2 (enExample) |
| CA (1) | CA3109513A1 (enExample) |
| CL (2) | CL2021000437A1 (enExample) |
| CO (1) | CO2021003608A2 (enExample) |
| EA (1) | EA202190601A1 (enExample) |
| IL (1) | IL280745A (enExample) |
| MX (1) | MX2021002165A (enExample) |
| MY (1) | MY204368A (enExample) |
| PH (1) | PH12021550322A1 (enExample) |
| SG (1) | SG11202101608XA (enExample) |
| WO (1) | WO2020041537A1 (enExample) |
| ZA (1) | ZA202100919B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202190601A1 (ru) | 2018-08-23 | 2021-07-14 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕ |
| GB2607746B (en) * | 2020-01-31 | 2025-05-21 | Leiman Allen Randy | Methods and kit for detection of analytes |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| BRPI0515589A (pt) | 2004-09-02 | 2008-07-29 | Genentech Inc | polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit |
| CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| SMT201900372T1 (it) | 2010-02-08 | 2019-09-09 | Regeneron Pharma | Topo con catena leggera comune |
| US9868786B2 (en) * | 2011-04-12 | 2018-01-16 | University Of Cincinnati | Methods for suppressing allergic reactions |
| WO2012169741A2 (ko) | 2011-06-07 | 2012-12-13 | (주)네오팜 | ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
| CN104293738A (zh) | 2013-09-11 | 2015-01-21 | 李莉 | 一种抗人FcεRⅠα亚基单克隆抗体及其应用 |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| AU2015303142B2 (en) | 2014-08-13 | 2020-08-06 | Suppremol Gmbh | Novel antibodies directed to Fc gamma receptor IIB and Fc epsilon receptor |
| CN104800164B (zh) | 2015-04-13 | 2017-11-07 | 上海市第一人民医院 | 一种雷公藤免疫纳米粒及用途 |
| CN108290951B (zh) | 2015-09-23 | 2022-04-01 | 瑞泽恩制药公司 | 优化抗cd3双特异性抗体和其用途 |
| BR112018070998A2 (pt) | 2016-04-13 | 2019-02-26 | Sanofi | proteínas de ligação triespecíficas e/ou trivalentes |
| RS64691B1 (sr) | 2016-09-23 | 2023-11-30 | Regeneron Pharma | Bispecifična anti-muc16-cd3 antitela i konjugati anti-muc16 sa lekom |
| EA202190601A1 (ru) | 2018-08-23 | 2021-07-14 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕ |
-
2019
- 2019-08-22 EA EA202190601A patent/EA202190601A1/ru unknown
- 2019-08-22 WO PCT/US2019/047601 patent/WO2020041537A1/en not_active Ceased
- 2019-08-22 EP EP19765582.2A patent/EP3840841A1/en active Pending
- 2019-08-22 KR KR1020217008580A patent/KR20210049863A/ko not_active Ceased
- 2019-08-22 JP JP2021510030A patent/JP7402223B2/ja active Active
- 2019-08-22 CA CA3109513A patent/CA3109513A1/en active Pending
- 2019-08-22 US US16/547,910 patent/US11578127B2/en active Active
- 2019-08-22 AU AU2019325565A patent/AU2019325565B2/en active Active
- 2019-08-22 MY MYPI2021000853A patent/MY204368A/en unknown
- 2019-08-22 CN CN201980069380.5A patent/CN112888482B/zh active Active
- 2019-08-22 SG SG11202101608XA patent/SG11202101608XA/en unknown
- 2019-08-22 MX MX2021002165A patent/MX2021002165A/es unknown
- 2019-08-22 BR BR112021003023-9A patent/BR112021003023A2/pt unknown
-
2021
- 2021-02-09 IL IL280745A patent/IL280745A/en unknown
- 2021-02-10 ZA ZA2021/00919A patent/ZA202100919B/en unknown
- 2021-02-15 PH PH12021550322A patent/PH12021550322A1/en unknown
- 2021-02-19 CL CL2021000437A patent/CL2021000437A1/es unknown
- 2021-03-19 CO CONC2021/0003608A patent/CO2021003608A2/es unknown
-
2023
- 2023-01-12 US US18/153,522 patent/US12441797B2/en active Active
- 2023-02-13 CL CL2023000442A patent/CL2023000442A1/es unknown
- 2023-10-03 JP JP2023172194A patent/JP7541167B2/ja active Active